HopeStage
Back to all studies
CompletedNCT03325556

Pimavanserin or Placebo to Prevent Relapse in Dementia-Related Psychosis

About this titleRead the official source — NCT03325556
Medication studyAges 50–90Multiple countriesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 50 years to 90 years.

Listed locations
Costa Mesa and 82 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 27, 2017
Recruitment status
Completed
Enrollment listed in the registry
392
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, United Kingdom, ...
Age range
From 50 Years to 90 Years
Official registry ID
NCT03325556
Official title
Show the full official title

A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Costa Mesa, United States · Fullerton, United States · Aventura, United States

67 more locations
  • Boca Raton, United States
  • Miami, United States
  • Naples, United States
  • Orlando, United States
  • Ormond Beach, United States
  • Pompano Beach, United States
  • Winfield, United States
  • Kansas City, United States
  • Quincy, United States
  • Chesterfield, United States
  • St Louis, United States
  • Las Vegas, United States
  • Eatontown, United States
  • Toms River, United States
  • Albany, United States
  • New York, United States
  • Staten Island, United States
  • North Canton, United States
  • Philadelphia, United States
  • Willow Grove, United States
  • Knoxville, United States
  • Charlottesville, United States
  • Rousse, Bulgaria
  • Antofagasta, Chile
  • Santiago, Chile
  • Hradec Králové, Czechia
  • Prague, Czechia
  • Rychnov nad Kněžnou, Czechia
  • Marseille, France
  • Toulouse, France
  • Tübingen, Germany
  • Padova, Italy
  • Rome, Italy
  • Torino, Italy
  • Bydgoszcz, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Siemianowice Śląskie, Poland
  • Szczecin, Poland
  • Warsaw, Poland
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Banská Bystrica, Slovakia
  • Košice, Slovakia
  • Krompachy, Slovakia
  • Svidník, Slovakia
  • Vranov nad Topľou, Slovakia
  • Barcelona, Spain
  • Sant Cugat del Vallès, Spain
  • Seville, Spain
  • Oleksandrivka, Ukraine
  • Dnipro, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • Vinnytsia, Ukraine
  • Zaporizhzhya, Ukraine
  • Bath, United Kingdom
  • Blackpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including Placebo, Pimavanserin 34 mg and Pimavanserin 20 mg.

Who was this study for?

Listed age limits: 50 years to 90 years.

Want to explore more studies?

Explore studies